- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02958384
A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Shiqi Li, MD
- Phone Number: 0086-13206140093
- Email: Lystch@qq.com
Study Locations
-
-
Chongqing
-
Chongqing, Chongqing, China, 400000
- Recruiting
- Southwest Hospital of Third Millitary Medical University
-
Contact:
- Zhi Yang, PhD
- Phone Number: 008613206140093
- Email: Lystch@qq.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- LeY-expressing myeloid malignancy must be assured and must be relapsed or refractory disease. According to current traditional therapies, there must be no available alternative curative therapies and subjects must be either ineligible for allogeneic stem cell transplant (SCT), have refused SCT, or have disease activity that prohibits SCT at this time.
- Patients enrolled must have an evaluated score above 60 with KPS.
- LeY expression of the malignant cells must be detected by immunohistochemistry or by flow cytometry.
- Gender is not limited, age from 14 years to 75 years.
- Patients must have measurable or evaluable disease at the time of enrollment, which may include any evidence of disease including minimal residual disease detected by flow cytometry, cytogenetics, or polymerase chain reaction (PCR) analysis.
- Patients are expected to survive for more than 3 months by their physicians at the time of enrollment.
- Adequate absolute CD3 count estimated need to be assured for obtaining target cell dose based on dosage cohorts.
Subjects with the following CNS status are eligible only in the absence of neurologic symptoms suggestive of CNS leukemia, such as cranial nerve palsy:
CNS 1, defined as absence of blasts in cerebral spinal fluid (CSF) on cytospin preparation, regardless of the number of WBCs; CNS 2, defined as presence of < 5/uL WBCs in CSF and cytospin positive for blasts, or > 5/uL WBCs but negative by Steinherz/Bleyer algorithm CNS3 with marrow disease who has failed salvage systemic and intensive IT chemotherapy (and therefore not eligible for radiation)
- Ability to give informed consent.
- Cardiac function: Left ventricular ejection fraction greater than or equal to 40% by MUGA or cardiac MRI, or fractional shortening greater than or equal to 28% by ECHO or left ventricular ejection fraction greater than or equal to 50% by ECHO.
- Renal function: Creatinine level of peripheral blood is required no greater than 133umol/L.
- Females of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects on the fetus.
- Patients with history of allogeneic stem cell transplantation are eligible if there is no evidence of active GVHD and no longer taking immunosuppressive agents for at least 30 days prior to enrollment.
- Patients volunteer to participate in the research.
Exclusion Criteria:
- Evident signs suggesting that patients are potentially allergic to cytokines.
- Frequent infection history and recent infection is uncontrolled.
- Patients with concomitant genetic syndrome: patients with Down syndrome, Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome
- Active acute or chronic graft-versus-host disease (GVHD) or requirement of immunosuppressant medications for GVHD within 4 weeks of enrollment.
- Concurrent use of systemic steroids or chronic use of immunosuppressant medications. Recent or current use of inhaled steroids is not exclusionary. For additional details regarding use of steroid and immunosuppressant medications.
- Pregnancy and nursing females.
- HIV infection.
- Active hepatitis B or active hepatitis C.
- Participation in a prior investigational study within 4 weeks prior to enrollment or longer if required by local regulation. Participation in non-therapeutic research studies is allowed.
- Class III/IV cardiovascular disability according to the New York Heart Association Classification.
- Patients with a known history or prior diagnosis of other serious immunologic, malignant or inflammatory disease.
- Other situations we think not eligible for participation in the research.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Myeloid Malignancies
The trial will be conducted in a manner of simon two-stage design with Anti-LeY-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with myeloid malignancies.
Only when the expected reaction rate is achieved the 30 patients left can be recruited.
|
The first 3 enrolled patients will receive autologous-derived LeY-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy.
If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events That Are Related to Treatment
Time Frame: 3 years
|
Determine the toxicity profile of the LeY targeted CAR T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0.
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Reaction Rate of Treatment
Time Frame: 3 years
|
3 years
|
In vivo existence of Anti-LeY CAR-T cells
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Cheng Qian, MD, PhD, Biotherapy Center of Southwest Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TMMU-BTC-012
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myeloid Malignancies
-
Gilead SciencesCompletedMyeloid MalignanciesUnited States, Australia, United Kingdom
-
Southwest Hospital, ChinaUnknown
-
Sichuan UniversityRecruitingMyeloid MalignanciesChina
-
Cristina GasparettoAgilent Technologies, Inc.Active, not recruitingLymphoid Malignancies | Myeloid MalignanciesUnited States
-
M.D. Anderson Cancer CenterNot yet recruitingMyeloid Malignancies | Lymphodepleting ChemotherapyUnited States
-
Catherine BollardJohns Hopkins University; Children's National Research InstituteRecruitingRelapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDSUnited States
-
ExCellThera inc.Memorial Sloan Kettering Cancer CenterRecruitingCord Blood Transplant | High Risk Myeloid MalignanciesUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States
-
iCell Gene TherapeuticsiCar Bio TherapeuticsNot yet recruitingHigh Risk Hematologic Malignancies | Relapsed and/or Refractory Acute Myeloid LeukemiaChina
-
Gruppo Italiano Trapianto di Midollo OsseoCompleted
Clinical Trials on Anti-LeY-CAR-transduced T cells
-
Southwest Hospital, ChinaUnknown
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.The First People's Hospital of Hefei; Hefei Binhu HospitalUnknownMalignant Glioma of Brain | Gastric Carcinoma | Colorectal CarcinomaChina
-
Southwest Hospital, ChinaUnknown
-
Southwest Hospital, ChinaUnknown
-
Southwest Hospital, ChinaUnknown
-
Southwest Hospital, ChinaUnknownLymphoma | Leukemia | Multiple MyelomaChina
-
Southwest Hospital, ChinaUnknown
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.The First People's Hospital of Hefei; Hefei Binhu HospitalUnknownHepatocellular Carcinoma | Non-small Cell Lung Cancer | Pancreatic Carcinoma | Triple-Negative Invasive Breast CarcinomaChina
-
Affiliated Hospital to Academy of Military Medical...Unknown
-
Peter MacCallum Cancer Centre, AustraliaCompleted